APAC In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospital, Pharma, Biotech, CROs) - Forecast to 2027
The Asia Pacific in situ hybridization market is projected to reach USD 744 million by 2027 from USD 363 million in 2022, at a CAGR of 15.4% during the forecast period. Companion diagnostic products showcase a significant potential to improve the diagnosis and treatment of cancer. FISH-based biomarkers play a substantial role in developing companion diagnostics because of their ability to evaluate morphology and gene amplification simultaneously. This has increased the adoption of ISH-based consumables across companion diagnostic tests.
“The kits & reagents segment accounted for the highest share in the Asia Pacific ISH consumables market revenue for the year 2021”
The ISH market is segmented into 3 key products, namely, consumables, instruments, and software. The ISH consumables market is further segmented into kits & reagents, probes, and accessories. The advantages of kits are their ease of use, availability of ready-to-use reagents and antibodies, the optimized sensitivity of the antibody to an antigen, and decreased chances of errors. This has propelled the use of kits in diagnostic tools employed for cancer patients to identify eligibility for specific drugs during treatment.
“Hospitals & diagnostic laboratories accounted for the largest revenue share of the ISH market in 2021”
Based on the end users the Asia Pacific in situ hybridization market is segmented into hospital & diagnostic laboratories, academic and research institutes, CROs, and pharmaceutical & biotechnology companies. Hospital & diagnostic laboratories segment has generated the highest revenue in 2021. The growing patient population, increasing Medicare reimbursement for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests are some of the key factors driving the growth of this end-user segment.
“China: The fastest-growing country in the Asia Pacific in situ hybridization market”
The Asia Pacific in situ hybridization market is segmented into Japan, China, India, South Korea, Taiwan, Singapore, Australia, New Zealand, and Rest of Asia Pacific. China market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. The economic growth in the country, its large population base, the rising prevalence of chronic diseases, improvements in the standard of living, growing demand for quality medical care, increasing healthcare spending, government initiatives, and awareness regarding the use of tissue diagnostic tests are the major factors driving market growth in the country.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the Asia Pacific in situ hybridization market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, technology, applications, end user, and country. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Asia Pacific in situ hybridization market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
“The kits & reagents segment accounted for the highest share in the Asia Pacific ISH consumables market revenue for the year 2021”
The ISH market is segmented into 3 key products, namely, consumables, instruments, and software. The ISH consumables market is further segmented into kits & reagents, probes, and accessories. The advantages of kits are their ease of use, availability of ready-to-use reagents and antibodies, the optimized sensitivity of the antibody to an antigen, and decreased chances of errors. This has propelled the use of kits in diagnostic tools employed for cancer patients to identify eligibility for specific drugs during treatment.
“Hospitals & diagnostic laboratories accounted for the largest revenue share of the ISH market in 2021”
Based on the end users the Asia Pacific in situ hybridization market is segmented into hospital & diagnostic laboratories, academic and research institutes, CROs, and pharmaceutical & biotechnology companies. Hospital & diagnostic laboratories segment has generated the highest revenue in 2021. The growing patient population, increasing Medicare reimbursement for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests are some of the key factors driving the growth of this end-user segment.
“China: The fastest-growing country in the Asia Pacific in situ hybridization market”
The Asia Pacific in situ hybridization market is segmented into Japan, China, India, South Korea, Taiwan, Singapore, Australia, New Zealand, and Rest of Asia Pacific. China market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. The economic growth in the country, its large population base, the rising prevalence of chronic diseases, improvements in the standard of living, growing demand for quality medical care, increasing healthcare spending, government initiatives, and awareness regarding the use of tissue diagnostic tests are the major factors driving market growth in the country.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 80% and Demand Side 20%
- By Designation: C-level - 25%, D-level - 20%, and Others - 55%
- Abbott (US)
- Abbott Laboratories (US)
- Thermo Fisher Scientific (US)
- Danaher Corporation (US)
- Merck (Germany)
- F. Hoffmann-La Roche (Switzerland)
- BioView (Israel)
- Agilent Technologies (US)
- Biocare Medical (US)
- Bio-Techne Corporation (US)
- QIAGEN (Germany)
- PerkinElmer (US)
- Enzo Biochem (US)
- Bio-Rad Laboratories (US)
- Abnova Corporation (Taiwan)
- BioGenex Laboratories (US)
- OpGen (US)
- Bio SB (US)
- Abcam (UK)
- Zytomed (Germany)
- 10x Genomics Inc. (US)
- NeoGenomics Laboratories (US).
This report provides a detailed picture of the Asia Pacific in situ hybridization market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, technology, applications, end user, and country. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Asia Pacific in situ hybridization market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: APAC IN SITU HYBRIDIZATION MARKET
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)
FIGURE 4 APAC IN SITU HYBRIDIZATION MARKET SIZE, 2021 (USD MILLION)
FIGURE 5 APAC IN SITU HYBRIDIZATION MARKET: FINAL CAGR PROJECTIONS (2022?2027)
FIGURE 6 APAC IN SITU HYBRIDIZATION MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, OPPORTUNITIES, AND CHALLENGES
2.3 MARKET DATA ESTIMATION & TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 INDUSTRY INSIGHTS
2.5 RESEARCH ASSUMPTIONS
3 EXECUTIVE SUMMARY
FIGURE 8 APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 9 APAC IN SITU HYBRIDIZATION MARKET SHARE, BY PRODUCT, 2021
FIGURE 10 APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 11 APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET SHARE, BY TYPE, 2021
FIGURE 12 APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 APAC IN SITU HYBRIDIZATION MARKET OVERVIEW
FIGURE 13 GROWING FOCUS ON COMPANION DIAGNOSTICS AND INCREASING CANCER INCIDENCE TO FAVOR MARKET GROWTH
4.2 APAC IN SITU HYBRIDIZATION MARKET, BY END USER, 2021 VS. 2027 (USD MILLION)
FIGURE 14 HOSPITAL & DIAGNOSTIC LABORATORIES TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 APAC IN SITU HYBRIDIZATION MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 APAC IN SITU HYBRIDIZATION MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of genetic disorders and cancer
TABLE 2 NEW CASES OF CANCER IN ASIA, 2020 VS. 2025
FIGURE 16 HEMOPHILIA OCCURRENCE, BY REGION
5.2.1.2 Growing awareness about companion diagnostics
5.2.2 OPPORTUNITIES
5.2.2.1 Untapped markets in developing countries
5.2.3 CHALLENGES
5.2.3.1 Shortage of skilled professionals
5.3 PORTER’S FIVE FORCES ANALYSIS
TABLE 3 APAC IN SITU HYBRIDIZATION MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT FROM NEW ENTRANTS
5.3.2 THREAT FROM SUBSTITUTES
5.3.3 BARGAINING POWER OF BUYERS
5.3.4 BARGAINING POWER OF SUPPLIERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 17 SUPPLY CHAIN ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET
5.5 VALUE CHAIN ANALYSIS
FIGURE 18 VALUE CHAIN ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET
5.6 ECOSYSTEM ANALYSIS
FIGURE 19 ECOSYSTEM ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET
5.7 KEY CONFERENCES & EVENTS IN 2022–2023
TABLE 4 KEY CONFERENCES & EVENTS, 2022–2023
5.8 REGULATORY ANALYSIS
5.8.1 FDA APPROVALS
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 PRICING ANALYSIS
TABLE 6 PRICING ANALYSIS OF IN SITU HYBRIDIZATION PRODUCTS
5.9.1 APAC IN SITU HYBRIDIZATION MARKET: AVERAGE SELLING PRICE TRENDS
TABLE 7 PRICING ANALYSIS OF FISH TESTS IN INDIA (2021)
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IN SITU HYBRIDIZATION MARKET IN ASIA PACIFIC
5.10.2 BUYING CRITERIA FOR IN SITU HYBRIDIZATION MARKET IN ASIA PACIFIC
FIGURE 21 KEY BUYING CRITERIA FOR END USERS
6 APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 8 APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
6.2 CONSUMABLES
TABLE 9 APAC IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 10 APAC IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.1 PROBES
6.2.1.1 Growing preference for direct localization of DNA/RNA sequences using probes to drive market
TABLE 11 APAC IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.2 KITS & REAGENTS
6.2.2.1 Growing focus on companion diagnostics to boost demand
TABLE 12 APAC IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.3 ACCESSORIES
6.2.3.1 Use of accessories for optimal performance of FISH and CISH probes to propel adoption
TABLE 13 APAC IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 RISING NEED FOR AUTOMATED SYSTEMS TO SUPPORT MARKET
TABLE 14 APAC IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 SOFTWARE
6.4.1 GROWING DEMAND FOR HIGH-SPEED SAMPLE DATA ANALYSIS TO DRIVE MARKET
TABLE 15 APAC IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
7 APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION
7.1 INTRODUCTION
TABLE 16 APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.2 CANCER DIAGNOSTICS
7.2.1 GROWING IMPORTANCE OF COMPANION DIAGNOSTICS TO DRIVE MARKET
TABLE 17 APAC IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 CYTOLOGY
7.3.1 GROWING DEMAND FOR FISH FOR DETECTION OF CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET
TABLE 18 APAC IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 INFECTIOUS DISEASE DIAGNOSTICS
7.4.1 NEED FOR HIGH SENSITIVITY AND SPECIFICITY IN INFECTIOUS DISEASE DIAGNOSIS TO AID GROWTH
TABLE 19 APAC IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
7.5 NEUROSCIENCE
7.5.1 RISING BURDEN OF NEUROLOGICAL DISORDERS TO BOOST R&D ACTIVITIES
TABLE 20 APAC IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION)
7.6 IMMUNOLOGY
7.6.1 RISING INCIDENCE OF AUTOIMMUNE DISEASES TO DRIVE GROWTH
TABLE 21 APAC IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
8 APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
TABLE 22 APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
8.2 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
TABLE 23 APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 24 APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.2.1 DNA FLUORESCENCE IN SITU HYBRIDIZATION
8.2.1.1 Need to ensure stability of genetic material to drive market
TABLE 25 APAC DNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.2.2 RNA FLUORESCENCE IN SITU HYBRIDIZATION
8.2.2.1 Increasing biomedical research to support market growth
TABLE 26 APAC RNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.2.3 PNA FLUORESCENCE IN SITU HYBRIDIZATION
8.2.3.1 Increased applications in infectious disease diagnosis to boost market
TABLE 27 APAC PNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 CHROMOGENIC IN SITU HYBRIDIZATION (CISH)
8.3.1 COST-EFFECTIVENESS OF CISH OVER FISH TO BOOST MARKET GROWTH
TABLE 28 APAC CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
9 APAC IN SITU HYBRIDIZATION MARKET, BY END USER
9.1 INTRODUCTION
TABLE 29 APAC IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 HOSPITAL & DIAGNOSTIC LABORATORIES
9.2.1 GROWING VOLUME OF MOLECULAR TESTS TO DRIVE MARKET
TABLE 30 APAC IN SITU HYBRIDIZATION MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 ACADEMIC & RESEARCH INSTITUTES
9.3.1 GROWING RESEARCH ON CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET
TABLE 31 APAC IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.4.1 NEED TO DEVELOP PRECISION TREATMENTS TO DRIVE DEMAND FOR ISH
TABLE 32 APAC IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
9.5 CONTRACT RESEARCH ORGANIZATIONS
9.5.1 INCREASING OUTSOURCING OF RESEARCH ACTIVITIES TO BOOST MARKET
TABLE 33 APAC IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
10 APAC IN SITU HYBRIDIZATION MARKET, BY COUNTRY
10.1 INTRODUCTION
FIGURE 22 APAC IN SITU HYBRIDIZATION MARKET SNAPSHOT
TABLE 34 APAC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
10.1.1 JAPAN
10.1.1.1 Growing focus on personalized diagnostics to support market growth
TABLE 35 JAPAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 36 JAPAN: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 37 JAPAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 38 JAPAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 39 JAPAN: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 40 JAPAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.1.2 CHINA
10.1.2.1 China to register highest CAGR during forecast period
TABLE 41 CHINA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 42 CHINA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 43 CHINA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 44 CHINA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 45 CHINA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 46 CHINA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.1.3 INDIA
10.1.3.1 Collaborations between hospitals and diagnostic labs to propel market growth in India
TABLE 47 INDIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 48 INDIA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 49 INDIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 50 INDIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 51 INDIA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 52 INDIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.1.4 SOUTH KOREA
10.1.4.1 Robust healthcare infrastructure to boost growth
TABLE 53 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 54 SOUTH KOREA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 55 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 56 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 57 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 58 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.1.5 TAIWAN
10.1.5.1 Improving cancer research and care to propel demand for ISH
TABLE 59 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 60 TAIWAN: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 61 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 62 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 63 TAIWAN: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 64 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.1.6 SINGAPORE
10.1.6.1 Government initiatives to make cancer treatment more affordable to contribute to growth
TABLE 65 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 66 SINGAPORE: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 67 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 68 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 69 SINGAPORE: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 70 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.1.7 AUSTRALIA
10.1.7.1 Increasing public-private investments in cancer research to boost demand
TABLE 71 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 72 AUSTRALIA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 73 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 74 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 75 AUSTRALIA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.1.8 NEW ZEALAND
10.1.8.1 Rising cases of cancer to propel growth
TABLE 77 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 78 NEW ZEALAND: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 79 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 80 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 81 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 82 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.1.9 REST OF ASIA PACIFIC
TABLE 83 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 84 REST OF ASIA PACIFIC: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 85 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 86 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 87 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 88 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 RIGHT-TO-WIN STRATEGIES ADOPTED BY KEY PLAYERS
TABLE 89 APAC IN SITU HYBRIDIZATION MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
11.3 MARKET SHARE ANALYSIS
FIGURE 23 APAC IN SITU HYBRIDIZATION MARKET SHARE ANALYSIS (2021)
11.4 REVENUE SHARE ANALYSIS
FIGURE 24 REVENUE ANALYSIS OF KEY COMPANIES (2019?2021)
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 25 APAC IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX (2021)
11.6 COMPETITIVE SCENARIO AND TRENDS
11.6.1 PRODUCT LAUNCHES
TABLE 90 APAC IN SITU HYBRIDIZATION MARKET: PRODUCT LAUNCHES, 2019–2022
11.6.2 DEALS
TABLE 91 APAC IN SITU HYBRIDIZATION MARKET: DEALS, 2019–2022
12 COMPANY PROFILES
12.1 KEY COMPANIES
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 ABBOTT LABORATORIES
TABLE 92 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 26 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
12.1.2 F. HOFFMANN-LA ROCHE AG
TABLE 93 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
FIGURE 27 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
12.1.3 THERMO FISHER SCIENTIFIC, INC.
TABLE 94 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 28 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
12.1.4 DANAHER CORPORATION
TABLE 95 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 29 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
12.1.5 AGILENT TECHNOLOGIES, INC.
TABLE 96 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 30 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021)
12.1.6 BIOCARE MEDICAL
TABLE 97 BIOCARE MEDICAL: BUSINESS OVERVIEW
12.1.7 BIO-TECHNE CORPORATION
TABLE 98 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
FIGURE 31 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2021)
12.1.8 QIAGEN N.V.
TABLE 99 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 32 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
12.1.9 MERCK KGAA
TABLE 100 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2021)
12.1.10 PERKINELMER
TABLE 101 PERKINELMER: BUSINESS OVERVIEW
FIGURE 34 PERKINELMER: COMPANY SNAPSHOT (2021)
12.1.11 ENZO BIOCHEM
TABLE 102 ENZO BIOCHEM: BUSINESS OVERVIEW
FIGURE 35 ENZO BIOCHEM: COMPANY SNAPSHOT (2021)
12.1.12 BIO-RAD LABORATORIES
TABLE 103 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
FIGURE 36 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)
12.1.13 ABNOVA CORPORATION
TABLE 104 ABNOVA CORPORATION: BUSINESS OVERVIEW
12.1.14 BIOGENEX LABORATORIES
TABLE 105 BIOGENEX LABORATORIES: BUSINESS OVERVIEW
12.1.15 OPGEN INC.
TABLE 106 OPGEN INC.: BUSINESS OVERVIEW
FIGURE 37 OPGEN INC.: COMPANY SNAPSHOT (2021)
12.1.16 BIO SB
TABLE 107 BIO SB: BUSINESS OVERVIEW
12.1.17 ABCAM
TABLE 108 ABCAM: BUSINESS OVERVIEW
FIGURE 38 ABCAM: COMPANY SNAPSHOT (2021)
12.1.18 ZYTOMED SYSTEMS GMBH
TABLE 109 ZYTOMED SYSTEMS GMBH: BUSINESS OVERVIEW
12.1.19 NEOGENOMICS LABORATORIES
TABLE 110 NEOGENOMICS LABORATORIES: BUSINESS OVERVIEW
FIGURE 39 NEOGENOMICS LABORATORIES: COMPANY SNAPSHOT (2021)
12.1.20 BIOVIEW
TABLE 111 BIOVIEW: BUSINESS OVERVIEW
FIGURE 40 BIOVIEW: COMPANY SNAPSHOT (2021)
12.1.21 10X GENOMICS
TABLE 112 10X GENOMICS: BUSINESS OVERVIEW
FIGURE 41 10X GENOMICS: COMPANY SNAPSHOT (2021)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: APAC IN SITU HYBRIDIZATION MARKET
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)
FIGURE 4 APAC IN SITU HYBRIDIZATION MARKET SIZE, 2021 (USD MILLION)
FIGURE 5 APAC IN SITU HYBRIDIZATION MARKET: FINAL CAGR PROJECTIONS (2022?2027)
FIGURE 6 APAC IN SITU HYBRIDIZATION MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, OPPORTUNITIES, AND CHALLENGES
2.3 MARKET DATA ESTIMATION & TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 INDUSTRY INSIGHTS
2.5 RESEARCH ASSUMPTIONS
3 EXECUTIVE SUMMARY
FIGURE 8 APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 9 APAC IN SITU HYBRIDIZATION MARKET SHARE, BY PRODUCT, 2021
FIGURE 10 APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 11 APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET SHARE, BY TYPE, 2021
FIGURE 12 APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 APAC IN SITU HYBRIDIZATION MARKET OVERVIEW
FIGURE 13 GROWING FOCUS ON COMPANION DIAGNOSTICS AND INCREASING CANCER INCIDENCE TO FAVOR MARKET GROWTH
4.2 APAC IN SITU HYBRIDIZATION MARKET, BY END USER, 2021 VS. 2027 (USD MILLION)
FIGURE 14 HOSPITAL & DIAGNOSTIC LABORATORIES TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 APAC IN SITU HYBRIDIZATION MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 APAC IN SITU HYBRIDIZATION MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of genetic disorders and cancer
TABLE 2 NEW CASES OF CANCER IN ASIA, 2020 VS. 2025
FIGURE 16 HEMOPHILIA OCCURRENCE, BY REGION
5.2.1.2 Growing awareness about companion diagnostics
5.2.2 OPPORTUNITIES
5.2.2.1 Untapped markets in developing countries
5.2.3 CHALLENGES
5.2.3.1 Shortage of skilled professionals
5.3 PORTER’S FIVE FORCES ANALYSIS
TABLE 3 APAC IN SITU HYBRIDIZATION MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT FROM NEW ENTRANTS
5.3.2 THREAT FROM SUBSTITUTES
5.3.3 BARGAINING POWER OF BUYERS
5.3.4 BARGAINING POWER OF SUPPLIERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 17 SUPPLY CHAIN ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET
5.5 VALUE CHAIN ANALYSIS
FIGURE 18 VALUE CHAIN ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET
5.6 ECOSYSTEM ANALYSIS
FIGURE 19 ECOSYSTEM ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET
5.7 KEY CONFERENCES & EVENTS IN 2022–2023
TABLE 4 KEY CONFERENCES & EVENTS, 2022–2023
5.8 REGULATORY ANALYSIS
5.8.1 FDA APPROVALS
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 PRICING ANALYSIS
TABLE 6 PRICING ANALYSIS OF IN SITU HYBRIDIZATION PRODUCTS
5.9.1 APAC IN SITU HYBRIDIZATION MARKET: AVERAGE SELLING PRICE TRENDS
TABLE 7 PRICING ANALYSIS OF FISH TESTS IN INDIA (2021)
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IN SITU HYBRIDIZATION MARKET IN ASIA PACIFIC
5.10.2 BUYING CRITERIA FOR IN SITU HYBRIDIZATION MARKET IN ASIA PACIFIC
FIGURE 21 KEY BUYING CRITERIA FOR END USERS
6 APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 8 APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
6.2 CONSUMABLES
TABLE 9 APAC IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 10 APAC IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.1 PROBES
6.2.1.1 Growing preference for direct localization of DNA/RNA sequences using probes to drive market
TABLE 11 APAC IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.2 KITS & REAGENTS
6.2.2.1 Growing focus on companion diagnostics to boost demand
TABLE 12 APAC IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.3 ACCESSORIES
6.2.3.1 Use of accessories for optimal performance of FISH and CISH probes to propel adoption
TABLE 13 APAC IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 RISING NEED FOR AUTOMATED SYSTEMS TO SUPPORT MARKET
TABLE 14 APAC IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 SOFTWARE
6.4.1 GROWING DEMAND FOR HIGH-SPEED SAMPLE DATA ANALYSIS TO DRIVE MARKET
TABLE 15 APAC IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
7 APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION
7.1 INTRODUCTION
TABLE 16 APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.2 CANCER DIAGNOSTICS
7.2.1 GROWING IMPORTANCE OF COMPANION DIAGNOSTICS TO DRIVE MARKET
TABLE 17 APAC IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 CYTOLOGY
7.3.1 GROWING DEMAND FOR FISH FOR DETECTION OF CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET
TABLE 18 APAC IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 INFECTIOUS DISEASE DIAGNOSTICS
7.4.1 NEED FOR HIGH SENSITIVITY AND SPECIFICITY IN INFECTIOUS DISEASE DIAGNOSIS TO AID GROWTH
TABLE 19 APAC IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
7.5 NEUROSCIENCE
7.5.1 RISING BURDEN OF NEUROLOGICAL DISORDERS TO BOOST R&D ACTIVITIES
TABLE 20 APAC IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION)
7.6 IMMUNOLOGY
7.6.1 RISING INCIDENCE OF AUTOIMMUNE DISEASES TO DRIVE GROWTH
TABLE 21 APAC IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
8 APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
TABLE 22 APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
8.2 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
TABLE 23 APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 24 APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.2.1 DNA FLUORESCENCE IN SITU HYBRIDIZATION
8.2.1.1 Need to ensure stability of genetic material to drive market
TABLE 25 APAC DNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.2.2 RNA FLUORESCENCE IN SITU HYBRIDIZATION
8.2.2.1 Increasing biomedical research to support market growth
TABLE 26 APAC RNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.2.3 PNA FLUORESCENCE IN SITU HYBRIDIZATION
8.2.3.1 Increased applications in infectious disease diagnosis to boost market
TABLE 27 APAC PNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 CHROMOGENIC IN SITU HYBRIDIZATION (CISH)
8.3.1 COST-EFFECTIVENESS OF CISH OVER FISH TO BOOST MARKET GROWTH
TABLE 28 APAC CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
9 APAC IN SITU HYBRIDIZATION MARKET, BY END USER
9.1 INTRODUCTION
TABLE 29 APAC IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 HOSPITAL & DIAGNOSTIC LABORATORIES
9.2.1 GROWING VOLUME OF MOLECULAR TESTS TO DRIVE MARKET
TABLE 30 APAC IN SITU HYBRIDIZATION MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 ACADEMIC & RESEARCH INSTITUTES
9.3.1 GROWING RESEARCH ON CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET
TABLE 31 APAC IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.4.1 NEED TO DEVELOP PRECISION TREATMENTS TO DRIVE DEMAND FOR ISH
TABLE 32 APAC IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
9.5 CONTRACT RESEARCH ORGANIZATIONS
9.5.1 INCREASING OUTSOURCING OF RESEARCH ACTIVITIES TO BOOST MARKET
TABLE 33 APAC IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
10 APAC IN SITU HYBRIDIZATION MARKET, BY COUNTRY
10.1 INTRODUCTION
FIGURE 22 APAC IN SITU HYBRIDIZATION MARKET SNAPSHOT
TABLE 34 APAC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
10.1.1 JAPAN
10.1.1.1 Growing focus on personalized diagnostics to support market growth
TABLE 35 JAPAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 36 JAPAN: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 37 JAPAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 38 JAPAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 39 JAPAN: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 40 JAPAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.1.2 CHINA
10.1.2.1 China to register highest CAGR during forecast period
TABLE 41 CHINA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 42 CHINA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 43 CHINA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 44 CHINA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 45 CHINA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 46 CHINA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.1.3 INDIA
10.1.3.1 Collaborations between hospitals and diagnostic labs to propel market growth in India
TABLE 47 INDIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 48 INDIA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 49 INDIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 50 INDIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 51 INDIA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 52 INDIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.1.4 SOUTH KOREA
10.1.4.1 Robust healthcare infrastructure to boost growth
TABLE 53 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 54 SOUTH KOREA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 55 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 56 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 57 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 58 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.1.5 TAIWAN
10.1.5.1 Improving cancer research and care to propel demand for ISH
TABLE 59 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 60 TAIWAN: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 61 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 62 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 63 TAIWAN: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 64 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.1.6 SINGAPORE
10.1.6.1 Government initiatives to make cancer treatment more affordable to contribute to growth
TABLE 65 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 66 SINGAPORE: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 67 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 68 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 69 SINGAPORE: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 70 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.1.7 AUSTRALIA
10.1.7.1 Increasing public-private investments in cancer research to boost demand
TABLE 71 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 72 AUSTRALIA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 73 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 74 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 75 AUSTRALIA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.1.8 NEW ZEALAND
10.1.8.1 Rising cases of cancer to propel growth
TABLE 77 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 78 NEW ZEALAND: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 79 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 80 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 81 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 82 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.1.9 REST OF ASIA PACIFIC
TABLE 83 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 84 REST OF ASIA PACIFIC: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 85 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 86 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 87 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 88 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 RIGHT-TO-WIN STRATEGIES ADOPTED BY KEY PLAYERS
TABLE 89 APAC IN SITU HYBRIDIZATION MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
11.3 MARKET SHARE ANALYSIS
FIGURE 23 APAC IN SITU HYBRIDIZATION MARKET SHARE ANALYSIS (2021)
11.4 REVENUE SHARE ANALYSIS
FIGURE 24 REVENUE ANALYSIS OF KEY COMPANIES (2019?2021)
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 25 APAC IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX (2021)
11.6 COMPETITIVE SCENARIO AND TRENDS
11.6.1 PRODUCT LAUNCHES
TABLE 90 APAC IN SITU HYBRIDIZATION MARKET: PRODUCT LAUNCHES, 2019–2022
11.6.2 DEALS
TABLE 91 APAC IN SITU HYBRIDIZATION MARKET: DEALS, 2019–2022
12 COMPANY PROFILES
12.1 KEY COMPANIES
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 ABBOTT LABORATORIES
TABLE 92 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 26 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
12.1.2 F. HOFFMANN-LA ROCHE AG
TABLE 93 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
FIGURE 27 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
12.1.3 THERMO FISHER SCIENTIFIC, INC.
TABLE 94 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 28 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
12.1.4 DANAHER CORPORATION
TABLE 95 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 29 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
12.1.5 AGILENT TECHNOLOGIES, INC.
TABLE 96 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 30 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021)
12.1.6 BIOCARE MEDICAL
TABLE 97 BIOCARE MEDICAL: BUSINESS OVERVIEW
12.1.7 BIO-TECHNE CORPORATION
TABLE 98 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
FIGURE 31 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2021)
12.1.8 QIAGEN N.V.
TABLE 99 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 32 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
12.1.9 MERCK KGAA
TABLE 100 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2021)
12.1.10 PERKINELMER
TABLE 101 PERKINELMER: BUSINESS OVERVIEW
FIGURE 34 PERKINELMER: COMPANY SNAPSHOT (2021)
12.1.11 ENZO BIOCHEM
TABLE 102 ENZO BIOCHEM: BUSINESS OVERVIEW
FIGURE 35 ENZO BIOCHEM: COMPANY SNAPSHOT (2021)
12.1.12 BIO-RAD LABORATORIES
TABLE 103 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
FIGURE 36 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)
12.1.13 ABNOVA CORPORATION
TABLE 104 ABNOVA CORPORATION: BUSINESS OVERVIEW
12.1.14 BIOGENEX LABORATORIES
TABLE 105 BIOGENEX LABORATORIES: BUSINESS OVERVIEW
12.1.15 OPGEN INC.
TABLE 106 OPGEN INC.: BUSINESS OVERVIEW
FIGURE 37 OPGEN INC.: COMPANY SNAPSHOT (2021)
12.1.16 BIO SB
TABLE 107 BIO SB: BUSINESS OVERVIEW
12.1.17 ABCAM
TABLE 108 ABCAM: BUSINESS OVERVIEW
FIGURE 38 ABCAM: COMPANY SNAPSHOT (2021)
12.1.18 ZYTOMED SYSTEMS GMBH
TABLE 109 ZYTOMED SYSTEMS GMBH: BUSINESS OVERVIEW
12.1.19 NEOGENOMICS LABORATORIES
TABLE 110 NEOGENOMICS LABORATORIES: BUSINESS OVERVIEW
FIGURE 39 NEOGENOMICS LABORATORIES: COMPANY SNAPSHOT (2021)
12.1.20 BIOVIEW
TABLE 111 BIOVIEW: BUSINESS OVERVIEW
FIGURE 40 BIOVIEW: COMPANY SNAPSHOT (2021)
12.1.21 10X GENOMICS
TABLE 112 10X GENOMICS: BUSINESS OVERVIEW
FIGURE 41 10X GENOMICS: COMPANY SNAPSHOT (2021)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
